Journal Mobile Options
Table of Contents
Vol. 51, No. 2, 2005
Issue release date: March 2005
Neuropsychobiology 2005;51:77–85

Dysregulated Innate Immune Responses in Young Children with Autism Spectrum Disorders: Their Relationship to Gastrointestinal Symptoms and Dietary Intervention

Jyonouchi H. · Geng L. · Ruby A. · Zimmerman-Bier B.
Department of Pediatrics, New Jersey Medical School, UMDNJ, Newark, N.J., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: Our previous study indicated an association between cellular immune reactivity to common dietary proteins (DPs) and excessive proinflammatory cytokine production with endotoxin (lipopolysaccharide, LPS), a major stimulant of innate immunity in the gut mucosa, in a subset of autism spectrum disorder (ASD) children. However, it is unclear whether such abnormal LPS responses are intrinsic in these ASD children or the results of chronic gastrointestinal (GI) inflammation secondary to immune reactivity to DPs. This study further explored possible dysregulated production of proinflammatory and counter-regulatory cytokines with LPS in ASD children and its relationship to GI symptoms and the effects of dietary intervention measures. Methods: This study includes ASD children (median age 4.8 years) on the unrestricted (n = 100) or elimination (n = 77) diet appropriate with their immune reactivity. Controls include children with non-allergic food hypersensitivity (NFH; median age 2.9 years) on the unrestricted (n = 14) or elimination (n = 16) diet, and typically developing children (median age 4.5 years, n = 13). The innate immune responses were assessed by measuring production of proinflammatory (TNF-α, IL-1β, IL-6, and IL-12) and counter-regulatory (IL-1ra, IL-10, and sTNFRII) cytokines by peripheral blood mononuclear cells (PBMCs) with LPS. The results were also compared to T-cell responses with common DPs and control T-cell mitogens assessed by measuring T-cell cytokine production. Results: ASD and NFH PBMCs produced higher levels of TNF-α with LPS than controls regardless of dietary interventions. However, only in PBMCs from ASD children with positive gastrointestinal (GI(+)) symptoms, did we find a positive association between TNF-α levels produced with LPS and those with cow’s milk protein (CMP) and its major components regardless of dietary interventions. In the unrestricted diet group, GI(+) ASD PBMCs produced higher IL-12 than controls and less IL-10 than GI(–) ASD PBMCs with LPS. GI(+) ASD but not GI(–) ASD or NFH PBMCs produced less counter-regulatory cytokines with LPS in the unrestricted diet group than in the elimination diet group. There was no significant difference among the study groups with regard to cytokine production in responses to T-cell mitogens and other recall antigens. Conclusion: Our results revealed that there are findings limited to GI(+) ASD PBMCs in both the unrestricted and elimination diet groups. Thus our findings indicate intrinsic defects of innate immune responses in GI(+) ASD children but not in NFH or GI(–) ASD children, suggesting a possible link between GI and behavioral symptoms mediated by innate immune abnormalities.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ: Intestinal lymphocyte population in children with regressive autism: Evidence for extensive mucosal immunopathology. J Clin Immunol 2003;23:504–517.
  2. Torrente F, Ashwood P, Day R, Machado N, Furlano RI, Anthony A, Davies SE, Wakefield AJ, Thomson MA, Maker-Smith JA, Murch SH: Small intestinal enteropathy with epithelial IgG and complement deposition in children with regressive autism. Mol Psychiatry 2002;7:375–382.
  3. Furlano R, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz MM, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH: Colonic CD8 and γδ T-cell infiltration with epithelial damage in children with autism. J Pediatr 2001;138:3663–3672.
  4. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tioson JT: Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999;135:559–563.
  5. Comi AM, Zimerman AW, Frye VH, Law PA, Peeden JN: Familial clustering of autoimmunedisorders and evaluation of medical risk factors in autism. J Child Neurol 1999;14:388–394.
  6. White JF: Intestinal pathophysiology in autism. Exp Biol Med 2003;228:639–649.
  7. Ilan K, Xiao-Song H, Gershwin ME, Yehuda S. Immune factors in autism: A critical review. J Autism Dev Disord 2002;32:337–345.
  8. Korvatska E, Ven de Water J, Anders TF, Gershwin ME: Genetic and immunologic considerations in autism. Neurobiol Dis 2002;9:102–125.

    External Resources

  9. Barton GM, Medzhitov R: Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol 2002;14:380–383.
  10. Beutler B: Innate immunity: An overview. Mol Immunol 2004;30:845–859.
  11. Rivest S: Molecular insights on the cerebral innate immune system. Brain Behav Immun 2003;17:13–19.
  12. Jyonouchi H, Sun S, Le H: Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001;120:170–179.
  13. Pasare C, Medzhitov R: Toll like receptors: Balancing host resistance with immune tolerance. Curr Opin Immunol 2003;15:677–682.
  14. Jyonouchi H, Sun S, Itokazu N: Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology 2002;46:76–84.
  15. Ono SJ: Molecular genetics of allergic diseases. Annu Rev Immunol 2000;8:347–366.
  16. Haller D, Jobin C: Interaction between resident luminal bacteria and host: Can a healthy relationship turn sour? J Pediatr Gastroenterol Nutr 2004:38:123–136.
  17. Medzhitov R, Janeway C Jr: Innate immunity. N Engl J Med 2000;343:338–344.
  18. Dantzer R: Innate immunity at the forefront of psychoneuroimmunology. Brain Behav Immun 2004;18:1–6.
  19. Dunn AJ, Wang J, Ando T: Effects of cytokines on cerebral neurotransmission: Comparison with the effects of stress. Adv Exp Med Biol 1999;461:117–127.
  20. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;47:911–920.
  21. Erb KJ, Wholleben G: Novel vaccine protecting against the development of allergic disorders: A double-edged sword? Curr Opin Immunol 2002;14:633–642.
  22. Benlounes N, Candalh C, Matarazzo P, Dupont C, Heyman M: The time-course of milk antigen-induced TNF-α secretion differs according to the clinical symptoms in children with cow’s milk protein. J Allergy Clin Immunol 1999;104:863–869.
  23. Chung HL, Hwang JB, Park JJ, Kim SG: Expression of transforming growth factor β1, transforming growth factor type I and II receptors, and TNF-α in the mucosa of the small intestine in infants with food protein-induced enterocolitis syndrome. J Allergy Clin Immunol 2001;109:150–154.
  24. Motrich RD, Gottero, C, Rezzonico, C, Rezzonico C, Riera CM, RIvero V: Cow’s milk stimulated lymphocyte proliferation and TNF-α secretion in hypersensitivity to cow’s milk protein. Clin Immunol 2003;109:203–211.
  25. Sampson HA, Anderson JA: Summary and recommendations: Classification of gastrointestinal manifestations due to immunologic reactions to foods in infants and young children. J Pediatr Gastroenterol Nutr 2000;30:S87–S94.

    External Resources

  26. Vercelli D: Genetics, epigenetics, and the environment: Switching, buffering, releasing. J Allergy Clin Immunol 2004;113:381–386.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50